Bicara Therapeutics Inc. filed a Form S-8 registration statement with the SEC on November 9, 2026, registering an additional 250,000 shares of common stock under its 2026 Inducement Plan, as amended.

Key Highlights

  • Shares registered: 250,000 additional shares of common stock, par value $0.0001 per share, under the 2026 Inducement Plan, as amended.
  • Board approval: The board of directors approved the amendment to the Inducement Plan on September 15, 2026, reserving the additional shares.
  • Purpose: The shares are reserved exclusively for equity-based awards to individuals who were not previously employees or directors of the company, as an inducement material to their entry into employment.
  • Plan basis: The Inducement Plan was originally adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market.
  • Prior registrations: This filing follows earlier Form S-8 filings relating to the same Inducement Plan, filed on March 30, 2026 (File No. 333-294748) and August 11, 2026 (File No. 333-298235).
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

Bicara Therapeutics Expands 2026 Inducement Plan With 250,000 Additional Shares

According to the filing, Bicara Therapeutics Inc. registered an additional 250,000 shares of common stock, par value $0.0001 per share, to be issued under the company's 2026 Inducement Plan, as amended. The registration statement incorporates by reference the information contained in prior Form S-8 filings related to the same plan and presents only new information not included in those earlier statements.

The filing disclosed that on September 15, 2026, the board of directors approved an amendment to the Inducement Plan under which the additional 250,000 shares were reserved. These shares are to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the company, serving as an inducement material to each individual's entry into employment. The plan was originally adopted by the board without stockholder approval, relying on Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market.

The registration statement was signed on November 9, 2026, by Ryan Cohlhepp, Pharm.D., in his capacity as President, Chief Operating Officer, and Interim Chief Executive Officer, and by Jennifer Larson, Chief Financial Officer. The filing also named Claire Mazumdar, Ph.D., as Chief Executive Officer and Director among the signatories. Goodwin Procter LLP provided the legal opinion filed as Exhibit 5.1, and KPMG LLP provided its consent as independent registered public accounting firm.

What Was Disclosed

Bicara Therapeutics filed a Form S-8 on November 9, 2026, to register 250,000 additional shares of common stock under its 2026 Inducement Plan, as amended, following a board-approved amendment dated September 15, 2026, reserving those shares for new-hire equity awards.